RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

ARCA Biopharma P/E 2024

ARCA Biopharma P/E

-5.67

ARCA Biopharma Dividend yield

Ticker

ABIO

ISIN

US00211Y5069

WKN

A2PGY6

As of May 20, 2024, ARCA Biopharma's P/E ratio was -5.67, a 67.75% change from the -3.38 P/E ratio recorded in the previous year.

The ARCA Biopharma P/E history

ARCA Biopharma Aktienanalyse

What does ARCA Biopharma do?

ARCA Biopharma Inc. is a biopharmaceutical company specializing in the development of therapies for cardiovascular diseases. The company was founded in 2004 and is headquartered in Westminster, Colorado, USA. ARCA Biopharma develops novel drugs tailored to the needs of patients with cardiovascular diseases. The history of ARCA Biopharma began when the company acquired exclusive rights to a technology for identifying genetic mutations associated with increased susceptibility to cardiovascular diseases. Thanks to this technology, ARCA Biopharma was able to develop more targeted, effective therapies based on the patient's genetic makeup. ARCA Biopharma's business model is based on the development of therapeutic technologies for cardiovascular diseases. The company utilizes its expertise in genomic research to develop customized, innovative drug therapies that are more targeted to the patient's genetic needs. ARCA Biopharma conducts intensive research and development work to develop significantly more effective drugs that are aimed at revolutionizing the market. ARCA Biopharma offers various types of medical therapies tailored to the needs of patients with cardiovascular diseases. The company focuses on RNA drug development and genomic research. RNA drugs are a relatively new type of medical therapy based on the regulation of gene expression. The company has several products in various stages of development tailored to the needs of patients with cardiovascular diseases. One of ARCA Biopharma's most successful products is Gencaro, a novel drug used in the treatment of heart failure. Gencaro is a beta-blocker specifically designed for patients with genetic markers associated with increased susceptibility to cardiovascular diseases. ARCA Biopharma has received multiple awards and numerous accolades for its innovation and research work. The company has partnerships with leading research and development organizations around the world to maximize its research efforts and accelerate the development of new innovative drugs. Overall, ARCA Biopharma aims to improve the lives of patients with cardiovascular diseases by providing tailored therapies that meet the genetic needs of the patient. The company has gained a reputation for its innovative research work and the development of highly effective drugs, and will undoubtedly play a leading role in the future development of therapies for cardiovascular diseases. ARCA Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering ARCA Biopharma's P/E Ratio

The Price to Earnings (P/E) Ratio of ARCA Biopharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing ARCA Biopharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of ARCA Biopharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in ARCA Biopharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about ARCA Biopharma Stock

What is the price-to-earnings ratio of ARCA Biopharma?

The price-earnings ratio of ARCA Biopharma is currently -5.67.

How has the price-earnings ratio of ARCA Biopharma changed compared to last year?

The price-to-earnings ratio of ARCA Biopharma has increased by 67.75% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of ARCA Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of ARCA Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of ARCA Biopharma affect the company?

An increase in the price-earnings ratio of ARCA Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of ARCA Biopharma affect the company?

A decrease in the price-earnings ratio of ARCA Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of ARCA Biopharma?

Some factors that influence the price-earnings ratio of ARCA Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does ARCA Biopharma pay?

Over the past 12 months, ARCA Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARCA Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of ARCA Biopharma?

The current dividend yield of ARCA Biopharma is .

When does ARCA Biopharma pay dividends?

ARCA Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARCA Biopharma?

ARCA Biopharma paid dividends every year for the past 0 years.

What is the dividend of ARCA Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARCA Biopharma located?

ARCA Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARCA Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARCA Biopharma from 5/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/20/2024.

When did ARCA Biopharma pay the last dividend?

The last dividend was paid out on 5/20/2024.

What was the dividend of ARCA Biopharma in the year 2023?

In the year 2023, ARCA Biopharma distributed 0 USD as dividends.

In which currency does ARCA Biopharma pay out the dividend?

The dividends of ARCA Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ARCA Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ARCA Biopharma

Our stock analysis for ARCA Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARCA Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.